Be ready.
When minutes matterTM
with thawed INTERCEPT® Fibrinogen Complex (IFC),
the only immediate source* of fibrinogen with a 5-day post-thaw shelf life.
INTERCEPT® FIBRINOGEN COMPLEX (IFC)
is approved specifically for the treatment and control of bleeding, including massive hemorrhage,
associated with fibrinogen deficiency.1
The IFC Advantage
5-Day Post-Thaw Shelf Life
Transfuse
Immediately*
Protect
Patients†
Minimize
Wastage
Control Bleeding
† Broad spectrum transfusion transmitted infection risk reduction.
Be ready. When minutes matterTM
Transfuse Immediately*
When controlling hemorrhage, faster is better.
DELAY INCREASES MORTALITY2
Every minute of delay between the activation of a massive transfusion protocol (MTP) and the arrival of the first blood products, results in a 5% increase in the odds of mortality.2
5-day post-thaw shelf life allows IFC to be thawed in advance and available for immediate, empirical use.
Protect Patients
IFC provides broad spectrum transfusion transmitted infection (TTI) risk reduction by
inactivating viruses, bacteria, protozoans, and leukocytes.**
IFC is produced from plasma pathogen reduced by the
INTERCEPT® Blood System for Plasma.3
Minimize Wastage
Transfusion-ready*, room temperature IFC minimizes wait times and wastage rates,
addressing common inventory challenges.
Cryoprecipitated AHF Inventory Challenges
Long
Wait Times
15 min – 2.8 hours4,5
Stored frozen and typically thawed in round 2 or 3 of MTP6
Short
Shelf Life
4 – 6 hours7
Post thaw due in part
to infectious risk
High
Wastage Rates
7 – 33%6
Thawed cryo AHF
is wasted
Control Bleeding
IFC is an enriched source of fibrinogen, factor XIII, von Willebrand factor, and other
constituents, restoring clot strength and hemostasis.
Fibrinogen, factor XIII, and von
Willebrand factor add the clotting
strength needed to achieve stable clot
formation and restore hemostasis.8
The ready-to-use* pathogen reduced, fibrinogen enriched IFC treats and controls bleeding,
including massive hemorrhage, associated with fibrinogen deficiency.1
The IFC Advantage
5-Day Post-Thaw Shelf Life
Transfuse
Immediately*
Protect
Patients†
Minimize
Wastage
Control Bleeding
† Broad spectrum transfusion transmitted infection risk reduction.
Be ready. When minutes matterTM
You May Also Be Interested In
WHAT'S IN THE BAG? When Minutes Matter. INTERCEPT Fibrinogen Complex is an enriched source of key constituents in effective hemostasis for the treatment and control of hemorrhage.
CLOT GENERATION: Successfully regaining hemostasis during hemorrhage requires a complex balance of factors involved in clot initiation and construction.
RESOURCES: View our resources area for package inserts and product information.
*INTERCEPT Fibrinogen Complex is available for immediate use for up to 5 days when stored thawed; when stored frozen, requires thawing prior to use.
**There is no pathogen inactivation process that has been shown to eliminate all pathogens. Certain non-enveloped viruses (e.g., HAV, HEV, B19 and poliovirus) and Bacillus cereus spores have demonstrated resistance to the INTERCEPT process. For a full list of pathogens, please refer to package insert.
References
1. INTERCEPT Blood System for Cryoprecipitation [Package Insert] For the manufacturing of Pathogen Reduced Cryoprecipitated Fibrinogen Complex. Concord, CA: Cerus Corporation; January 20, 2021. 2. Meyer DE, Vincent LE, Fox EE, et al. Every minute counts: Time to delivery of initial massive transfusion cooler and its impact on mortality. The Journal of Trauma and Acute Care Surgery 2017;83:19-24. 3. INTERCEPT Blood System for Plasma [Package Insert] Concord, CA: Cerus Corporation; May 1, 2020. 4. Holcomb JB, Fox EE, Zhang X, et al. Cryoprecipitate Use in the Prospective Observational Multicenter Major Trauma Transfusion study (PROMMTT). The Journal of Trauma and Acute Care Surgery 2013;75:S31-S39. 5. AABB. Circular of Information for the Use of Human Blood and Blood Components. Bethesda, MD: AABB; 2017. 6. Dunbar NM, Olson NJ, Szczepiorkowski ZM, et al. Blood component transfusion and wastage rates in the setting of massive transfusion in three regional trauma centers. Transfusion 2017;57:45-52. 7. Wagner SJ, Hapip CA, Abel L. Bacterial safety of extended room temperature storage of thawed cryoprecipitate. Transfusion 2019;59;3549-50. 8. Chapin JC, Hajjar KA. Fibrinolysis and the control of blood coagulation. Blood Reviews 2015;29:17-24.